Drugs in Dev. Endocrinology
Phase II
South Korea 
Lead Product(s) : DD01
Therapeutic Area : Endocrinology
Study Phase : Phase II
Sponsor : DS Asset Management
Deal Size : $51.0 million
Deal Type : Series C Financing
Details : Proceeds will be used to advance DD01 into a Phase 2 clinical trial for obese patients with both diabetes and nonalcoholic fatty liver disease, continue support of Phase 2 studies of NLY01 in Parkinson’s and Alzheimer’s disease.
Product Name : DD01
Product Type : Peptide
Upfront Cash : Undisclosed
October 19, 2021
Lead Product(s) : DD01
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Sponsor : DS Asset Management
Deal Size : $51.0 million
Deal Type : Series C Financing
Lead Product(s) : Enavogliflozin
Therapeutic Area : Endocrinology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Daewoong Announces Korea's First-Ever SGLT2 Inhibitor for Diabetes Treatment
Details : Enavogliflozin administered in conjunction with diet and exercise showed statistically significant decrease in glycated hemoglobin (HbA1c) levels in comparison to the placebo starting from week 4, in type 2 diabetes patients with uncontrolled blood sugar...
Product Name : DWP16001
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 21, 2020
Lead Product(s) : Enavogliflozin
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
